MTMaria Christine Thurnheer

Maria Christine Thurnheer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maria Christine Thurnheer has a total of 143 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Protocol for the National Data Stream IICU: a multicentre Swiss platform integrating multimodal clinical and pathogen data for personalized prediction of infection-related outcomes in intensive care

    by Catherine R. Jutzeler, Karsten Borgwardt, Nora Toussaint, Magdalena Lukamowicz-Rajska, Manuel Battegay, Filippo Boroli, Silvio D. Brugger, Andrea Büchler, Thierry Calandra, Jean-Daniel Chiche, et al.

  • Open Access

    Nationwide, multicentre, prospective periprosthetic joint infection cohort study: study protocol of the Swiss Revision Cohort (REVCO)

    by Micol Pallanza, Atesch Ateschrang, Anders Boyd, Anna Conen, Antonios Kritikos, Jonathan Laurençon, Emanuel Francis Liechti, Sylvain Meylan, Truong-Thanh Pham, Sylvain Steinmetz, et al.

    Introduction: Diagnostic and therapeutic management of patients with periprosthetic joint infections (PJIs) remains challenging. This national cohort aims to describe the epidemiology, clinical phenotypes, management strategies and outcomes of patients with PJI. Methods and analysis: This is a national, multicentre, prospective, longitudinal, observational cohort study of patients who underwent revision for PJI of the hip, knee, shoulder, elbow or ankle. Participating centres are university or non-university tertiary healthcare facilities located in Switzerland. Episodes include likely and confirmed PJI, as defined by the European Bone and Joint Infection Society criteria. During routine clinical visits around revision surgery, data are collected and patients are followed-up thereafter for a minimum of 2 years. The primary objective is infection outcome and secondary objectives include functional outcome and patient satisfaction and evaluation of host, infection, microbiological and treatment factors associated with treatment failure and poor functional outcomes, both in the overall population and across subgroups. A minimum of 329 patients would be needed to have sufficient statistical power to carry out these analyses. Ethics and dissemination: Ethical approval has been granted by the Research Ethics Committee under protocol number 2021-01791. All patients provide written informed consent for inclusion in the study. Study findings will be disseminated through publications in peer-reviewed journals and presented at national and international conferences in the fields of orthopaedics, infectious diseases and microbiology. We plan to leverage the platform within the cohort to conduct future studies and interventional trials. Trial registration number: NCT07473089 .

  • Open Access

    Patterns of medical comorbidities among aging people receiving heroin-assisted treatment: A 10-year single-center repeated cross-sectional study

    by David Strittmatter, Dario Willi, Peer W. Brandt, Sonja Loebnitz, Eveline Hofmann, Maria Christine Thurnheer

  • Open Access

    Association of a polygenic risk score with low trauma fractures in people with HIV – The swiss HIV cohort study

    by Claudio Strickler, Christian W. Thorball, Isabella C. Schoepf, Johannes Schwenke, Barbara Hasse, Lene Ryom, Maria C. Thurnheer, Christoph Fux, Christian R. Kahlert, Enos Bernasconi, et al.

    Background: Polygenic risk scores (PRS) are likely to enter routine clinical care for individual disease risk prediction in the next 10 years. We recently showed that the bone mineral density-associated gSOS-PRS is independently associated with a > 4-fold increased risk of osteoporosis in the Swiss HIV Cohort Study (SHCS). Here we investigate whether this PRS is also associated with low trauma fractures (LTF) in people with HIV in the SHCS. Methods: Applying a case-control design, cases had a first LTF (1994–2022) and LTF-free controls were matched on age, sex and observation time. We obtained univariable odds ratios (OR) for LTF in SHCS participants of European descent, based on a genome-wide PRS built from 9413 LTF-associated single nucleotide polymorphisms (SNPs). In multivariable analysis, LTF odds ratios of the PRS were adjusted for non-genetic (traditional and HIV-related) LTF risk factor profile including potentially adverse antiretroviral exposures. Results: We included 277 SHCS participants with a first LTF (cases) and 796 LTF-free controls (median age 55 years; 68% male; 91% with suppressed HIV RNA). Participants with the most unfavorable genetic background (top quintile of the gSOS-PRS) had univariable and multivariable LTF-OR of 2.30 (95% confidence interval, 1.49–3.56) and 2.30 (1.43–3.72), respectively, compared to participants with the most favorable genetic background (bottom gSOS-PRS quintile). Participants with the most unfavorable non-genetic risk factor profile (top quintile) had an adjusted gSOS-OR of 7.42 (95% confidence interval [CI], 4.3–12.82), compared with participants in the bottom quintile. Conclusions: In people with HIV in Switzerland, an unfavorable PRS was independently associated with LTF risk after adjustment for traditional and HIV-related LTF risk factors.


  • Open Access

    Characteristics and comorbidities of patients on opioid agonist therapy in Switzerland: A descriptive analysis of the nationwide SAMMSU cohort

    by Michael Lütolf, Andrea Bregenzer, Philip Bruggmann, Alberto Moriggia, Claude Scheidegger, Katharina Hensel-Koch, Erika Castro Batänjer, Maria Christine Thurnheer, Pascale Della Santa, Oliver Senn, et al.


  • Open Access

    Perioperative Antibiotic Prophylaxis Duration in Patients Undergoing Cystectomy With Urinary Diversion

    by Maria C. Thurnheer, Astrid Schürmann, Markus Huber, Jonas Marschall, Patrick Y. Wuethrich, Fiona C. Burkhard

    Importance: Perioperative antibiotic prophylaxis (PAP) reduces the incidence of surgical site infections (SSIs). Guidelines recommend 24 hours or less of PAP for cystectomy with urinary diversion; however, evidence specifying optimal PAP duration for this surgery is lacking, and prolonged administration of PAP is common practice.Objective: To establish noninferiority of 24-hour PAP vs extended-duration PAP in preventing SSIs within 90 days after cystectomy with urinary diversion.Design, Setting, and Participants: This single-center, noninferiority randomized clinical trial was performed from April 18, 2018, to August 18, 2022, in patients aged older than 18 years undergoing elective open cystectomy with urinary diversion. Exclusion criteria were contraindications to administered drugs and inability to follow study procedures.Intervention: PAP administered for 24 hours (24-hour PAP group) vs PAP until all catheters and stents were removed (extended PAP group).Main Outcome and Measures: The primary end point was the rate of SSI, and the secondary end points included all-cause mortality, both within 90 days after surgery. Noninferiority of the 24-hour PAP treatment was assessed by comparing the 90% CI (corresponding to a significance level of α = .05) with the predefined noninferiority margin of 10%.Results: A total of 95 patients were randomly assigned to the 24-hour PAP group (median [IQR] age, 69.3 [63.1-76.8] years; 66 males [69.5%]) and 98 to the extended PAP group (median [IQR] age, 69.5 [60.8-75.5] years; 68 males [69.4%]). Patients in the 24-hour PAP group received PAP for a median of 1 day (IQR, 1-1 day), and patients in the extended PAP group received PAP for a median of 8 days (IQR, 7-10 days). No significant differences in SSIs occurring within 90 days were found (24-hour PAP group, 8 patients [8.4%]; extended PAP group, 12 patients [12.2%]; P = .53). The risk difference for 90-day cumulative SSI incidence was −3.8% (90% CI, −11.1% to 3.4%), establishing noninferiority of 24-hour PAP vs extended PAP to prevent SSI. Mortality was not significantly different between groups.Conclusions and Relevance: The findings of this randomized clinical trial demonstrate noninferiority of 24-hour PAP vs extended-duration PAP in preventing SSIs within 90 days after cystectomy with urinary diversion and may contribute to antibiotic stewardship efforts in urology.Trial Registration: ClinicalTrials.gov Identifier: NCT03305627


  • Open Access

    Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study

    by Suraj Balakrishna, Luisa Salazar-Vizcaya, Axel J. Schmidt, Viacheslav Kachalov, Katharina Kusejko, Maria Christine Thurnheer, Jan A. Roth, Dunja Nicca, Matthias Cavassini, Manuel Battegay, et al.

    Over the last decade, syphilis diagnoses among men-who-have-sex-with-men (MSM) have strongly increased in Europe. Understanding the drivers of the ongoing epidemic may aid to curb transmissions. In order to identify the drivers of syphilis transmission in MSM in Switzerland between 2006 and 2017 as well as the effect of potential interventions, we set up an epidemiological model stratified by syphilis stage, HIV-diagnosis, and behavioral factors to account for syphilis infectiousness and risk for transmission. In the main model, we used ‘reported non-steady partners’ (nsP) as the main proxy for sexual risk. We parameterized the model using data from the Swiss HIV Cohort Study, Swiss Voluntary Counselling and Testing center, cross-sectional surveys among the Swiss MSM population, and published syphilis notifications from the Federal Office of Public Health. The main model reproduced the increase in syphilis diagnoses from 168 cases in 2006 to 418 cases in 2017. It estimated that between 2006 and 2017, MSM with HIV diagnosis had 45.9 times the median syphilis incidence of MSM without HIV diagnosis. Defining risk as condomless anal intercourse with nsP decreased model accuracy (sum of squared weighted residuals, 378.8 vs. 148.3). Counterfactual scenarios suggested that increasing screening of MSM without HIV diagnosis and with nsP from once every two years to twice per year may reduce syphilis incidence (at most 12.8% reduction by 2017). Whereas, increasing screening among MSM with HIV diagnosis and with nsP from once per year to twice per year may substantially reduce syphilis incidence over time (at least 63.5% reduction by 2017). The model suggests that reporting nsP regardless of condom use is suitable for risk stratification when modelling syphilis transmission. More frequent screening of MSM with HIV diagnosis, particularly those with nsP may aid to curb syphilis transmission.


  • Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection

    by Gail V. Matthews, Sanjay Bhagani, Juergen Rockstroh, Jordan J. Feld, Andri Rauch, Christine Thurnheer, Julie Bruneau, Arthur Kim, Margaret Hellard, David Shaw, et al.